TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 18, 2025--

Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate when compared with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2 positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. Results were presented today ( 291O ) alongside the results from the DESTINY-Breast05 ( LBA1 ) phase 3 trial during Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.